S _qary Loss of heterozygosity (LOH) on chromosome 13 occurs on 25-30% of breast tumours. This may reflect the inactivation of the retinobLastoma susceptibility gene RBI. However . As LOH is thought to reflect the inactivation of one allele of a tumour-suppressor gene, the retinoblastoma susceptibility gene (RB)), present on chromosomal band 13q14 could be the target for these LOH events. Structural abnormalities in RB) have been reported in primary breast cancs and in breast cancer cell lines (Lee et al., 1988; rAng et al., 1988; Varley et al., 1989) . However, allele loss at the RB) locus in breast and also in ovarian carcinomas is not correlated with loss of RBl protein expression (Borg et al., 1992; Dodson et al., 1994; Kim et al., 1994) . This suggests the presence of another tumour-suppressor gene adjacent to RB).
Loss of heterozygosity (LOH) on chromosome 13 occurs in approximately 25% of primary breast tumours . As LOH is thought to reflect the inactivation of one allele of a tumour-suppressor gene, the retinoblastoma susceptibility gene (RB)), present on chromosomal band 13q14 could be the target for these LOH events. Structural abnormalities in RB) have been reported in primary breast cancs and in breast cancer cell lines (Lee et al., 1988; rAng et al., 1988; Varley et al., 1989) . However, allele loss at the RB) locus in breast and also in ovarian carcinomas is not correlated with loss of RBl protein expression (Borg et al., 1992; Dodson et al., 1994; Kim et al., 1994) . This suggests the presence of another tumour-suppressor gene adjacent to RB).
The breast cancer susceptibility gene, BRCA2, has recently been localised to 13ql2-ql3 by genetic lnkage analysis (Wooster et al., 1994a) . In common with the BRCAJ gene on chromosome 17q21 (Miki et al., 1994) , mutations in BRCA2 confer susceptibility to early-onset breast cancer in women and to ovarian cancer, but the latter risk is probably lower than for BRCA). In contrast to BRCAJ, BRCA2 is associated with a substantially increased risk of breast cawer in men.
To investigate further the roles of BRCA2 and RBI in breast cancer development we have determined LOH in the 13ql2-ql4 chromosomal region in 200 sporadic breast carcinomas using 11 polymorphic microsatellite markers.
Materials an m
The 13ql2-ql4 polymorphic microsatellite markers used were D13S289, D13S290, AFM238zd9, AFM109xhl, D13S260, D13S171, D13S267, D13S219, D13S218, D13S155 and D13S153 (within RB)). (Gyapay et al., 1994; J Weissenbach, personal communication alele at all markers were used to calculate the probability of the wild-type DNA being homozygous at each locus. It was then possible to calculate the probability of the DNA being homozygous throughout the BRCA2 and RBI regions in the germine DNA (Table I ), e.g. the probability that cell line MDA157 has a contiguous zone of homozygosity for the markers D13S260, S171, S267, S219 and S218 is 1:895 656
Rests and .
Evaluation of the role of somatic mutations of BRCA2 in sporadic cancers is complicated by the presence of the RBI gene in the vicinity. Since RBI shows structural abnormalities in 15% of the primary breast tumours tested (T'Ang et Varley et al., 1989) , much of the LOH on 13q could be directed at RBI. However, expression of the RBI gene on chromosomal band 13q14 in tumours of the breast or the ovary does not correlate with LOH on chromosome 13q (Borg et al., 1992; Dodson et al., 1994; Kim et al., 1994) . Absence of RBJ staining is found in 15% of the breast tumours tested, and detected predominantly in tumours without LOH on 13q (Kim et al., 1994) . The incongruity between LOH in the RBI chromosomal region and RBI expression
may reflect the involvement of BRCA2 as a target for LOH. The results shown in Table II indicate that all tumours which showed LOH at RBI also showed LOH within the BRCA2 region. Similarly, all tumours which showed LOH at or RBI is the predominant target of the LOH on chromosome 13q. Three tumours were identfied which showed a transition from retention of heterozygosity to LOH at an adjacent marker, defined as a 'breakpoint', within the BRCA2 region as defined by linkage analysis (Wooster et al., 1994a ). BTl9 had a breakpoint between D13S260 and D13S171. BT42 and BT589 were not informative for D13S171. They showed a brekpoint between D13S260 and D13S267. Figure 1 shows the allelic imbalance factors and the Phosphorimager traces of the PCR products obtaied from these tumours using the markers that border the breakpoints. On the assumption that BRCA2 is the target for LOH in these tumours the results suggest that the candidate region for this gene is now decreased to 3 cM and defined by D13S260 (proximal) and D13S267 (distal). However, since all three breakpoint tumours also show LOH of RB), and hence RB) may be the tret of LOH, this mapping information may be misleading.
In addition to the 200 primary breast tumours, 12 breast cancer cell lines were examined. Although corresponding DNA from non-neoplastic issue was not available, each polymorphic marker used is beterozygous in a minimum of 64% of the cases (and usually more). It is therefore extrmly unlikely that an individual will be constitutionally homozygous for all polymorphisms in the chromosome 13q12-ql4 region. Since 7 of the 12 cell lines were homozygous at all markers examined it is likely that allele loss has occurred during development of the tumour or subsequently during culture in vitro. Table I shows the cell lnes and the aliele frequencies for cases with a contiguous region of homozygosity. The high frequency of plausible allele loss in the RBI region in cell lines (7 out of 12, 58%) compared with that in primary tumours (32.5%) corresponds well with the observation of rAng et al. (1988) that rearrangements in RB) occur more frequently in breast cancer cell lines than in primary breast tumours, suggesting an enhancement of cell line establishment as a result of RBI inactivation.
Of particular interest is ZR-75-1. This cell line is homozygous at all markers within or adjacent to the BRCA2 region but is heterozygous at both polymorphisms close to RBI, D13S155 and D13S153. The probability of such a contiguous zone of homozygosity in the BRCA2 region is less than 1:4000. This number is the multiplication sum of the allele frequencies for all markers in the BRCA2 region (Table   I ) and additionally from marker D13S220 (located between D13S267 and D13S219), of which the frequency for the allele in ZR-75-1 is 0.18. The results therefore suggest that this individual was constitutionally heterozygous at at least one marker but that LOH has occurred in the BRCA2 region and not at RBI. Consequently ZR-75-1 is the only breast cancer in this series indicating that BRCA2 is a distinct target for LOH on chromosome 13q in addition to RBI. However, we cannot exclude that LOH in the BRCA2 region occurred during cell lne establishment and was not present in the primary tumour. The results from ZR-75-1 do not decrease the idate region for BRCA2.
We have recently analysed allele loss on chromosome 13q
in breast cancers from a family showing strong evidence of linkag to BRCA2. Seven out of eight informative tumours showed LOH and in all cases it was the wild-type allele that was lost (Collins et al., 1995 
